Rx (Prescription Medicine)
USD $ 219.00
Bevaro 400mg Injection 是一种重要的药物，用于治疗多种严重的医学病症。其活性成分为 Bevacizumab，属于靶向治疗药物，可抑制血管内皮生长因子（VEGF）。VEGF 是一种蛋白质，在新血管形成过程中起关键作用，即血管生成。许多癌症依赖于血管生成来生长和转移。通过阻断 VEGF，Bevaro 400mg Injection 有助于使肿瘤缺血，从而减缓或停止其生长。
该注射剂适用于治疗特定类型的癌症，包括转移性结直肠癌、非鳞状非小细胞肺癌以及胶质母细胞瘤。通常由医护专业人员通过静脉给药。剂量和治疗时长取决于具体病情、病情严重程度以及患者的个体反应。常见的不良反应可能包括高血压、尿蛋白、鼻出血和疲劳。少见但严重的不良反应也可能发生，因此如有任何疑虑，请与医生讨论。Bevaro 400mg Injection 应储存在室温并避光保存。
| Medicine Form | |
|---|---|
| Rx Status | |
| Medicine Type | |
| Molecule | |
| Brand Name | |
| Strength | |
| Brand Name | |
| Molecule | |
| Strength | 400 mg |
| Medicine Form | Injection |
| Pack Quantity | 1 Vial |
| Packaging Type | Vial |
| Medicine Type | Generic |
| Country Of Origin | India |
| Rx Status | Rx (Prescription Medicine) |
其他品牌的 Bevacizumab 400 mg — 同一活性成分且强度相同，但来自不同制造商。
医学审核
Renu Meena, B.Pharm
Medical Content Writer
Renu Meena is an experienced Medical Content Writer with a strong foundation in pharmacy practice. She holds a Bachelor of Pharmacy (B.Pharm) degree from Rajasthan University of Health Sciences (RUHS), Jaipur, and is registered with the Rajasthan State Pharmacy Council (Reg. No. 55661). With 4+ years of experience across clinical pharmacy and medical content development, she creates evidence-based content for medicines, diseases, and patient education. Her work is shaped by a strong understanding of pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11, and safety reporting requirements. Renu focuses on making complex medical information simple, accurate, and useful for readers while maintaining high quality and compliance.
